




The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 7.6% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 123%, being 121% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	100,843
Cost of Goods Sold	0
Intangible Assets	16,836
Liabilities, Current	55,793
Liabilities, Non-Current	98,137
Other Assets	14,267
Other Compr. Net Income	-2,401
Other Expenses	41,712
Other Liabilities	0
Other Net Income	-536
Other Revenues	0
Property and Equipment	839
Research and Development	20,700
Selling, General and Administrative Expense	74,516

Output Variable	Value in 1000 USD
Assets	132,785
Liabilities	153,930
Expenses	136,928
Revenues	0
Stockholders Equity	-21,145
Net Income	-137,464
Comprehensive Net Income	-138,664
BaseVar	213,290
ECR before LimitedLiability	-129%
Economic Capital Ratio	123%